8-K Announcements
6Material company update
Mar 21, 2023·SEC
Material company update
Jan 31, 2023·SEC
Material company update
Nov 14, 2022·SEC
CASI Pharmaceuticals, Inc.(CASI)Earnings, Financials & Key Ratios
CASI•NASDAQ
Price updated May 1, 2026
AboutCASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's product pipeline includes CNCT19, an autologous CD19 CAR-T investigative product for the treatment of patients with B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL); BI-1206 that is in Phase I/II trial in combination with anti-PD1 therapy Keytruda for solid tumors, and in a Phase I/IIa trial in combination with MabThera (rituximab) in patients with relapsed/refractory NHL; and CB-5339, which is in Phase I clinical trial for acute myeloid leukemia and myelodysplastic syndrome. Its product pipeline also comprises CID-103 for the treatment of patients with multiple myeloma; Thiotepa, which has multiple indications including use as a conditioning treatment for various allogeneic haemopoietic stem cell transplants; and Octreotide long acting injectable formulations for the treatment of acromegaly and for the control of symptoms associated with various neuroendocrine tumors. The company has licensing agreements with Juventas Cell Therapy Ltd; BioInvent International AB; Black Belt Therapeutics Limited; and Cleave Therapeutics, Inc. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. The company was formerly known as EntreMed, Inc. and changed its name to CASI Pharmaceuticals, Inc. in June 2014. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Rockville, Maryland.Show more
- Revenue$29M-15.8%
- EBITDA-$37M-74.8%
- Net Income-$39M-45.7%
- EPS (Diluted)-2.56-26.7%
- Gross Margin39.06%-34.0%
- EBITDA Margin-130.67%-107.5%
- Operating Margin-138.84%-87.6%
- Net Margin-137.57%-73.0%
- ROE-301.8%-410.3%
CASI Key Insights
CASI Pharmaceuticals, Inc. (CASI) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 47.2%
- ✓Trading at only 1.2x book value
✗Weaknesses
- ✗High debt to equity ratio of 12.0x
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Shares diluted 14.8% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CASI posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CASI Price & Volume
CASI Pharmaceuticals, Inc. (CASI) stock price & volume — 10-year historical chart
Loading chart...
CASI Growth Metrics
CASI Pharmaceuticals, Inc. (CASI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years103.24%
5 Years47.19%
3 Years-1.84%
TTM21.72%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-59.58%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-41.7%
Return on Capital
10 Years-20.22%
5 Years-50.01%
3 Years-55.64%
Last Year-104.59%
CASI Peer Comparison
CASI Pharmaceuticals, Inc. (CASI) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ZLAB | 1.98B | 17.88 | -11.18 | 15.33% | -39.29% | -24.32% | 0.31 | |
 LEGN | 6.2B | 33.52 | -20.95 | 64.04% | -21.97% | -24.91% | 0.41 | |
 ZYME | 1.7B | 23.14 | -21.43 | 38.87% | -126.33% | -0.25% | 0.07 | |
 CAN | 209.89M | 0.33 | -0.74 | 96.69% | -39.68% | -60.72% | 0.13 | |
 HALO | 8.13B | 68.57 | 26.79 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ACAD | 3.7B | 21.60 | 9.43 | 11.87% | 34.3% | 35.65% | 0.04 | |
 SUPN | 2.51B | 43.58 | -64.09 | 8.63% | -3.74% | -2.73% | 0.04 | |
 LXRX | 906.16M | 2.04 | -14.57 | 60.24% | -37.46% | -18.64% | 0.58 |
Compare CASI vs Peers
CASI Pharmaceuticals, Inc. (CASI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CASI Income Statement
CASI Pharmaceuticals, Inc. (CASI) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 4.13M | 15.14M | 30.17M | 43.11M | 33.88M | 28.54M | 26.85M |
Revenue Growth % | -100% | - | - | - | 266.52% | 99.25% | 42.89% | -21.41% | -15.77% | 21.72% |
Cost of Goods Sold | 66.45K | 117.78K | 1.67M | 3.94M | 9.51M | 12.56M | 15.83M | 13.83M | 17.39M | 17.23M |
COGS % of Revenue | - | - | - | 95.26% | 62.8% | 41.62% | 36.72% | 40.81% | 60.94% | - |
Gross Profit | -66.45K▲ 0% | -117.78K▼ 77.2% | -1.67M▼ 1318.7% | 196K▲ 111.7% | 5.63M▲ 2774.0% | 17.61M▲ 212.6% | 27.28M▲ 54.9% | 20.05M▼ 26.5% | 11.15M▼ 44.4% | 9.61M▲ 0% |
Gross Margin % | - | - | - | 4.74% | 37.2% | 58.38% | 63.28% | 59.19% | 39.06% | 35.8% |
Gross Profit Growth % | -260.36% | -77.24% | -1318.7% | 111.73% | 2773.98% | 212.64% | 54.9% | -26.5% | -44.41% | - |
Operating Expenses | 9.42M | 10.75M | 26.5M | 40.19M | 58.41M | 59.13M | 53.77M | 45.13M | 50.77M | 54.71M |
OpEx % of Revenue | - | - | - | 972.82% | 385.8% | 195.99% | 124.74% | 133.22% | 177.9% | - |
Selling, General & Admin | 4.78M | 3.16M | 18M | 30.44M | 27.48M | 38.41M | 37.77M | 41.84M | 41.44M | 44.42M |
SG&A % of Revenue | - | - | - | 736.84% | 181.47% | 127.31% | 87.63% | 123.49% | 145.23% | - |
Research & Development | 4.65M | 7.6M | 8.51M | 9.75M | 11.47M | 14.42M | 16M | 9.86M | 8.92M | 8.74M |
R&D % of Revenue | - | - | - | 235.97% | 75.75% | 47.81% | 37.11% | 29.11% | 31.25% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 19.47M | 6.3M | 0 | -6.57M | 407K | 1.55M |
Operating Income | 9.42M▲ 0% | -10.75M▼ 214.1% | -26.5M▼ 146.5% | -39.99M▼ 50.9% | -52.78M▼ 32.0% | -41.52M▲ 21.3% | -26.49M▲ 36.2% | -25.08M▲ 5.3% | -39.62M▼ 58.0% | -45.09M▲ 0% |
Operating Margin % | - | - | - | -968.07% | -348.6% | -137.62% | -61.45% | -74.03% | -138.84% | -167.98% |
Operating Income Growth % | 31.71% | -214.13% | -146.52% | -50.88% | -31.98% | 21.34% | 36.19% | 5.33% | -57.98% | - |
EBITDA | 9.49M | -10.63M | -24.83M | -37.84M | -50.82M | -39.7M | -24.07M | -21.34M | -37.29M | -43.94M |
EBITDA Margin % | - | - | - | -915.95% | -335.66% | -131.6% | -55.84% | -62.99% | -130.67% | -163.66% |
EBITDA Growth % | 31.39% | -212.08% | -133.54% | -52.37% | -34.31% | 21.88% | 39.37% | 11.34% | -74.75% | -59.97% |
D&A (Non-Cash Add-back) | 66.45K | 117.78K | 1.67M | 2.15M | 1.96M | 1.81M | 2.42M | 3.74M | 2.33M | 1.17M |
EBIT | -9.42M | -10.76M | -27.46M | -39.58M | -33.31M | -35.22M | -26.49M | -25.28M | -37.2M | -42.54M |
Net Interest Income | -26.09K | 1.01K | 39.99K | 1.06M | 866K | 321K | 127K | 614K | -332K | -504K |
Interest Income | 7.72K | 15.98K | 48.2K | 1.06M | 866K | 321K | 189K | 614K | 539K | 132K |
Interest Expense | 33.81K | 14.98K | 8.21K | 0 | 0 | 0 | 62K | 0 | 871K | 636K |
Other Income/Expense | -32.88K | -18.88K | -967.57K | -5.37M | 5.27M | 5.67M | -11.79M | -1.21M | 1.55M | -2.11M |
Pretax Income | -9.45M▲ 0% | -10.77M▼ 13.9% | -27.47M▼ 155.1% | -45.36M▼ 65.1% | -47.51M▼ 4.7% | -35.84M▲ 24.6% | -38.28M▼ 6.8% | -26.29M▲ 31.3% | -38.07M▼ 44.8% | -47.2M▲ 0% |
Pretax Margin % | - | - | - | -1098.09% | -313.79% | -118.81% | -88.8% | -77.61% | -133.4% | -175.83% |
Income Tax | 33.81K | 14.98K | 0 | 0 | 0 | 0 | 1.98M | -81K | 1.19M | 2.17M |
Effective Tax Rate % | -0.36% | -0.14% | 0% | 0% | 0% | 0% | -5.17% | 0.31% | -3.12% | -4.61% |
Net Income | -9.45M▲ 0% | -10.77M▼ 13.9% | -27.47M▼ 155.1% | -45.36M▼ 65.1% | -48.29M▼ 6.4% | -36.65M▲ 24.1% | -41.01M▼ 11.9% | -26.94M▲ 34.3% | -39.26M▼ 45.7% | -49.38M▲ 0% |
Net Margin % | - | - | - | -1098.09% | -318.92% | -121.5% | -95.14% | -79.51% | -137.57% | -183.93% |
Net Income Growth % | -31.18% | -13.93% | -155.07% | -65.12% | -6.45% | 24.09% | -11.89% | 34.32% | -45.73% | -59.58% |
Net Income (Continuing) | -9.45M | -10.77M | -27.47M | -45.36M | -47.51M | -35.84M | -40.26M | -26.21M | -39.26M | -49.38M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 20.67M | 22.03M | 23.46M | 22.36M | 0 | 0 | 0 |
EPS (Diluted) | -1.69▲ 0% | -1.75▼ 3.6% | -3.24▼ 85.1% | -4.80▼ 48.1% | -4.37▲ 9.0% | -2.69▲ 38.4% | -3.01▼ 11.9% | -2.02▲ 32.9% | -2.56▼ 26.7% | -3.08▲ 0% |
EPS Growth % | 23.87% | -3.55% | -85.14% | -48.15% | 8.96% | 38.44% | -11.9% | 32.89% | -26.73% | -41.7% |
EPS (Basic) | -1.69 | -1.75 | -3.24 | -4.80 | -4.37 | -2.69 | -3.01 | -2.02 | -2.56 | - |
Diluted Shares Outstanding | 5.59M | 6.15M | 8.48M | 9.59M | 11.05M | 13.61M | 13.65M | 13.36M | 15.34M | 16.05M |
Basic Shares Outstanding | 5.59M | 6.15M | 8.48M | 9.59M | 11.05M | 13.61M | 13.65M | 13.36M | 15.34M | 16.05M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CASI Balance Sheet
CASI Pharmaceuticals, Inc. (CASI) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 27.45M | 43.81M | 92.56M | 61.5M | 74.03M | 61.97M | 73.42M | 59.34M | 39.58M | 11.91M |
Cash & Short-Term Investments | 27.09M | 43.49M | 85.12M | 54.25M | 66.37M | 48.57M | 51.34M | 30.77M | 16.09M | 4.68M |
Cash Only | 27.09M | 43.49M | 84.2M | 53.62M | 57.06M | 38.7M | 47.11M | 17.08M | 13.47M | 4.68M |
Short-Term Investments | 0 | 0 | 912.2K | 625K | 9.31M | 9.87M | 4.22M | 13.69M | 2.62M | 0 |
Accounts Receivable | 0 | 0 | 0 | 1.29M | 4.64M | 9.8M | 12.97M | 10.14M | 15.35M | 2.61M |
Days Sales Outstanding | - | - | - | 114.24 | 111.98 | 118.61 | 109.85 | 109.22 | 196.27 | 105.09 |
Inventory | 0 | 0 | 283K | 4.54M | 1.36M | 1.91M | 6.14M | 15.88M | 5.25M | 2.61M |
Days Inventory Outstanding | - | - | 61.82 | 421.3 | 52.06 | 55.43 | 141.55 | 419.12 | 110.23 | 81.6 |
Other Current Assets | 355.89K | 322.49K | 911.81K | 0 | 0 | 0 | 2.98M | 2.56M | 2.89M | 0 |
Total Non-Current Assets | 264.08K | 1.29M | 20.85M | 41.13M | 53.71M | 76.33M | 22.81M | 15.92M | 13.9M | 12.55M |
Property, Plant & Equipment | 229.59K | 1.05M | 1.75M | 9.69M | 10.76M | 21.82M | 13.23M | 11.63M | 11.36M | 9.95M |
Fixed Asset Turnover | - | - | - | 0.43x | 1.41x | 1.38x | 3.26x | 2.91x | 2.51x | 2.52x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 18.78M | 16.89M | 13.21M | 12.2M | 1.06M | 1.84M | 238K | 224K |
Long-Term Investments | 0 | 0 | 0 | 14.04M | 29.44M | 40.13M | 7.46M | 1.68M | 1.72M | 7.06M |
Other Non-Current Assets | 34.48K | 242.02K | 310.02K | 504K | 299K | 2.18M | 1.06M | 771K | 587K | 660K |
Total Assets | 27.71M▲ 0% | 45.1M▲ 62.7% | 113.41M▲ 151.5% | 102.63M▼ 9.5% | 127.73M▲ 24.5% | 138.3M▲ 8.3% | 96.23M▼ 30.4% | 75.27M▼ 21.8% | 53.67M▼ 28.7% | 24.46M▲ 0% |
Asset Turnover | - | - | - | 0.04x | 0.12x | 0.22x | 0.45x | 0.45x | 0.53x | 0.72x |
Asset Growth % | 375.65% | 62.74% | 151.46% | -9.5% | 24.46% | 8.27% | -30.42% | -21.79% | -28.69% | -159.01% |
Total Current Liabilities | 1.32M | 5.06M | 3.87M | 7.95M | 7.98M | 13.19M | 17M | 16.73M | 36.45M | 39.42M |
Accounts Payable | 1.06M | 2.09M | 968K | 5.11M | 3.26M | 4.79M | 3.29M | 4.44M | 2.72M | 560K |
Days Payables Outstanding | 5.85K | 6.47K | 211.45 | 474.27 | 125.15 | 139.2 | 75.85 | 117.15 | 57.15 | 27.97 |
Short-Term Debt | 0 | 0 | 1.5M | 0 | 1.29M | 2.17M | 0 | 0 | 18.39M | 18.86M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 2.62M | 2.54M | 2.47M | 2.47M |
Other Current Liabilities | 0 | 2.23M | 944 | -1.18M | 0 | -7.62M | 0 | 0 | 10.31M | 0 |
Current Ratio | 20.86x | 8.65x | 23.89x | 7.74x | 9.28x | 4.70x | 4.32x | 3.55x | 1.09x | 0.30x |
Quick Ratio | 20.86x | 8.65x | 23.82x | 7.17x | 9.11x | 4.56x | 3.96x | 2.60x | 0.94x | 0.24x |
Cash Conversion Cycle | - | - | - | 61.28 | 38.88 | 34.83 | 175.55 | 411.19 | 249.35 | 158.72 |
Total Non-Current Liabilities | 5.61M | 1.5M | 73.59K | 1.02M | 16.18M | 17.15M | 12.3M | 34.38M | 15.37M | 13.63M |
Long-Term Debt | 1.49M | 1.5M | 0 | 0 | 0 | 0 | 0 | 18.89M | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 0 | 1.02M | 965K | 1.1M | 476K | 1.62M | 2.54M | 2.54M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 4.12M | 0 | 73.59K | 0 | 12.87M | 13.22M | 11.82M | 13.87M | 12.84M | 13.63M |
Total Liabilities | 6.93M | 6.56M | 3.95M | 8.97M | 24.16M | 30.34M | 29.3M | 51.1M | 51.82M | 53.05M |
Total Debt | 1.49M | 1.5M | 1.5M | 2.2M | 3.2M | 4.33M | 1.34M | 21.24M | 22.14M | 18.86M |
Net Debt | -25.6M | -41.99M | -82.71M | -51.42M | -53.87M | -34.37M | -45.77M | 4.16M | 8.67M | 14.17M |
Debt / Equity | 0.07x | 0.04x | 0.01x | 0.02x | 0.03x | 0.04x | 0.02x | 0.88x | 11.96x | -0.66x |
Debt / EBITDA | 0.16x | - | - | - | - | - | - | - | - | -0.43x |
Net Debt / EBITDA | -2.70x | - | - | - | - | - | - | - | - | -0.32x |
Interest Coverage | -278.62x | -718.16x | -3345.93x | - | - | - | -427.27x | - | -42.71x | -66.88x |
Total Equity | 20.78M▲ 0% | 38.54M▲ 85.4% | 109.46M▲ 184.0% | 93.67M▼ 14.4% | 103.57M▲ 10.6% | 107.96M▲ 4.2% | 66.93M▼ 38.0% | 24.16M▼ 63.9% | 1.85M▼ 92.3% | -28.59M▲ 0% |
Equity Growth % | 441.42% | 85.43% | 184.02% | -14.43% | 10.58% | 4.23% | -38% | -63.9% | -92.34% | -876.14% |
Book Value per Share | 3.72 | 6.27 | 12.92 | 9.76 | 9.38 | 7.93 | 4.90 | 1.81 | 0.12 | -1.78 |
Total Shareholders' Equity | 20.78M | 38.54M | 109.46M | 73M | 81.54M | 84.5M | 44.57M | 24.16M | 1.85M | -28.59M |
Common Stock | 602.76K | 699.01K | 953.67K | 979K | 1.24M | 1.4M | 1K | 1K | 2K | 2K |
Retained Earnings | -441.93M | -452.7M | -478.94M | -523.91M | -570.5M | -605.64M | -637.16M | -660.82M | -700.08M | -735.09M |
Treasury Stock | -8.03M | -8.03M | -8.03M | -8.03M | -8.03M | -8.03M | -9.33M | -9.6M | -9.6M | -9.6M |
Accumulated OCI | -262.02K | -372.27K | -1.23M | -2.73M | 589K | 1.95M | -703K | -1.2M | -1.77M | -5.14M |
Minority Interest | 0 | 0 | 0 | 20.67M | 22.03M | 23.46M | 22.36M | 0 | 0 | 0 |
CASI Cash Flow Statement
CASI Pharmaceuticals, Inc. (CASI) cash flow — operating, investing & free cash flow history
| Metric | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -6.02M | -6.4M | -28.58M | -23.24M | -25.89M | -26.84M | -21.09M | -19.97M | -29.22M | 0 |
Operating CF Margin % | - | - | - | -562.65% | -170.97% | -88.98% | -48.92% | -58.94% | -102.41% | - |
Operating CF Growth % | -9.24% | -6.29% | -346.47% | 18.69% | -11.37% | -3.69% | 21.44% | 5.32% | -46.36% | 0% |
Net Income | -9.45M | -10.77M | -27.47M | -45.36M | -47.51M | -35.84M | -40.26M | -26.94M | -39.26M | -49.38M |
Depreciation & Amortization | 66.45K | 117.78K | 1.67M | 2.15M | 1.96M | 1.81M | 2.42M | 3.74M | 2.33M | 0 |
Stock-Based Compensation | 3M | 650.44K | 6.12M | 7.31M | 7.82M | 7.77M | 7.01M | 7.22M | 1.31M | 1.31M |
Deferred Taxes | -5.67K | 19.89K | 325.46K | 1.24M | -3.94M | -5.2M | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 26.31K | 7.48K | 553.57K | 6.97M | 19.1M | 7.83M | 16.39M | 3.83M | 5.63M | 48.07M |
Working Capital Changes | 348.04K | 3.57M | -9.78M | 4.45M | -3.32M | -3.22M | -6.65M | -7.82M | 771K | 0 |
Change in Receivables | 0 | 0 | 0 | -1.29M | -3.35M | -5.16M | -3.17M | 2.83M | -5.21M | 0 |
Change in Inventory | 0 | 0 | -283K | -4.41M | 3.19M | -551K | -4.23M | -9.74M | 5.83M | 0 |
Change in Payables | 180.53K | 849.37K | -1.1M | 4M | -1.54M | 1.49M | 1.07M | 1.15M | -1.72M | 0 |
Cash from Investing | -64.79K | -934.7K | -21.77M | -28.06M | -20.72M | -20.69M | 31.16M | -9.67M | 11.24M | 0 |
Capital Expenditures | -223.23K | -934.7K | -21.77M | -14.02M | -19.33M | -15.5M | -5.61M | -204K | -223K | 0 |
CapEx % of Revenue | - | - | - | 339.39% | 127.65% | 51.38% | 13.02% | 0.6% | 0.78% | 0% |
Acquisitions | 158.45K | 0 | -20.64M | 20M | 0 | 10K | 138K | 0 | -1.37M | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 158.45K | 0 | 20.64M | -6.97M | -1.31M | 7.03M | 6.44M | -2.04M | 483K | 0 |
Cash from Financing | 28.05M | 23.73M | 92.27M | 22.05M | 47.15M | 29.64M | -3.27M | -907K | 15.43M | 0 |
Debt Issued (Net) | 0 | 326K | 258K | -1.5M | 1.25M | -839K | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 28.15M | 23.87M | 87.99M | 182K | 45.1M | 32.5M | -3.27M | -169K | 15M | 0 |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -738K | -718K | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | -3.27M | -278K | 0 | 0 |
Other Financing | -96.51K | -462.84K | 4.02M | 23.36M | 805K | -2.02M | 0 | 0 | 1.15M | 0 |
Net Change in Cash | 21.96M▲ 0% | 16.4M▼ 25.3% | 40.71M▲ 148.3% | -30.58M▼ 175.1% | 3.44M▲ 111.3% | -18.36M▼ 633.3% | 8.41M▲ 145.8% | -30.03M▼ 457.1% | -3.62M▲ 88.0% | -11.85M▲ 0% |
Free Cash Flow | -6.25M▲ 0% | -7.34M▼ 17.5% | -50.36M▼ 586.4% | -37.26M▲ 26.0% | -45.21M▼ 21.3% | -42.34M▲ 6.3% | -26.7M▲ 36.9% | -22.21M▲ 16.8% | -29.46M▼ 32.7% | 0▲ 0% |
FCF Margin % | - | - | - | -902.03% | -298.61% | -140.35% | -61.94% | -65.55% | -103.25% | 0% |
FCF Growth % | -12.77% | -17.46% | -586.36% | 26% | -21.33% | 6.35% | 36.94% | 16.82% | -32.67% | - |
FCF per Share | -1.12 | -1.19 | -5.94 | -3.88 | -4.09 | -3.11 | -1.96 | -1.66 | -1.92 | 0.00 |
FCF Conversion (FCF/Net Income) | 0.64x | 0.59x | 1.04x | 0.51x | 0.54x | 0.73x | 0.51x | 0.74x | 0.74x | -0.00x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.81M | 0 | 0 |
CASI Key Ratios
CASI Pharmaceuticals, Inc. (CASI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -128.65% | -36.31% | -37.12% | -44.66% | -48.96% | -34.66% | -46.9% | -59.14% | -301.8% | 358.32% |
Return on Invested Capital (ROIC) | - | - | -170.59% | -86.93% | -86.1% | -50.51% | -41.94% | -76.02% | -153% | 1066.16% |
Gross Margin | - | - | - | 4.74% | 37.2% | 58.38% | 63.28% | 59.19% | 39.06% | 35.8% |
Net Margin | - | - | - | -1098.09% | -318.92% | -121.5% | -95.14% | -79.51% | -137.57% | -183.93% |
Debt / Equity | 0.07x | 0.04x | 0.01x | 0.02x | 0.03x | 0.04x | 0.02x | 0.88x | 11.96x | -0.66x |
Interest Coverage | -278.62x | -718.16x | -3345.93x | - | - | - | -427.27x | - | -42.71x | -66.88x |
FCF Conversion | 0.64x | 0.59x | 1.04x | 0.51x | 0.54x | 0.73x | 0.51x | 0.74x | 0.74x | -0.00x |
Revenue Growth | -100% | - | - | - | 266.52% | 99.25% | 42.89% | -21.41% | -15.77% | 21.72% |
Related:CASI Dividend History·CASI Revenue History·CASI Price History·CASI P/E History·CASI Financial Ratios·CASI Institutional Holders
CASI SEC Filings & Documents
CASI Pharmaceuticals, Inc. (CASI) SEC filings — annual & quarterly reports (10-K, 10-Q)
CASI Frequently Asked Questions
CASI Pharmaceuticals, Inc. (CASI) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
CASI Pharmaceuticals, Inc. (CASI) reported $26.8M in revenue for fiscal year 2024. This represents a 3629% increase from $0.7M in 1995.
CASI Pharmaceuticals, Inc. (CASI) saw revenue decline by 15.8% over the past year.
CASI Pharmaceuticals, Inc. (CASI) reported a net loss of $49.4M for fiscal year 2024.
Dividend & Returns
Yes, CASI Pharmaceuticals, Inc. (CASI) pays a dividend with a yield of 31.10%. This makes it attractive for income-focused investors.
CASI Pharmaceuticals, Inc. (CASI) has a return on equity (ROE) of -301.8%. Negative ROE indicates the company is unprofitable.
CASI Pharmaceuticals, Inc. (CASI) had negative free cash flow of $29.5M in fiscal year 2024, likely due to heavy capital investments.